Constipation

Constipation is a condition in which stool becomes hard, dry, and difficult to pass, and bowel movements don’t happen very often. Other symptoms may include painful bowel movements, and feeling bloated, uncomfortable, and sluggish.

What is Constipation?

Constipation is a condition characterized by inability to pass stools that become hard and more difficult to pass.

Constipation Diagnosis

Causes of Constipation

Constipation Treatments

Constipation Prevention

Constipation Symptoms

Constipation in Babies

Constipation in Children

Constipation in the Elderly

Drugs that Cause Constipation

Slow Transit Constipation

Latest Constipation News and Research

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Exoskeleton-assisted walking helps people with spinal cord injury evacuate stool more efficiently

A team of researchers has shown that physical intervention plans that included exoskeleton-assisted walking helped people with spinal cord injury evacuate more efficiently and improved the consistency of their stool.

29 May 2021

U.S. Marshals seized more than 207,000 units of adulterated dietary supplements containing kratom

The U.S. Food and Drug Administration announced today that U.S. Marshals, at the agency's request, seized more than 207,000 units of dietary supplements and bulk dietary ingredients that are or contain kratom, including over 34,000 kilograms of bulk kratom.

22 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

Rice University neurobiologist wins NIH grant to study enteric nervous system development

Rice University neurobiologist Rosa Uribe will be hitting the books for her latest study of the digestive system, but some of the pages in her books are a billion years old.

10 May 2021

New model may explain the perplexing asymmetrical motor symptoms in Parkinson's disease

Parkinson's disease (PD) is characterized by slowness of movement and tremors, which often appear asymmetrically in patients.

28 Apr 2021

Researchers harness the body's own ability to block pain

Fentanyl, oxycodone, morphine--these substances are familiar to many as a source of both pain relief and the cause of a painful epidemic of addiction and death.

26 Apr 2021

COVID-19 survivors have increased risk of death for at least six months

As the COVID-19 pandemic has progressed, it has become clear that many survivors -; even those who had mild cases -; continue to manage a variety of health problems long after the initial infection should have resolved.

23 Apr 2021

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

22 Apr 2021

Probiotic strain improves iron levels in healthy pregnant women

A new study published in Acta Obstetricia et Gynecologica Scandinavica found that taking a particular probiotic strain improves iron levels in healthy pregnant women and may therefore help to prevent iron deficiency.

21 Apr 2021

FDA approves immunotherapy for first-line treatment of advanced gastric cancer

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.

16 Apr 2021

Mice study points to a promising treatment for relieving colitis pain without side effects

A targeted opioid that only treats diseased tissues and spares healthy tissues relieves pain from inflammatory bowel disease without causing side effects, according to new research published in the journal Gut.

31 Mar 2021

FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

25 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

10 Mar 2021

Study finds increased opioid consumption two years after intensive care

Nearly 11 percent of people admitted to an intensive care unit in Sweden between 2010 and 2018 received opioid prescriptions on a regular basis for at least six months and up to two years after discharge.

2 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Researchers find potential biomarkers of Parkinson's disease

A research team led by Nagoya University in Japan has found that blood pressure, the hematocrit (the percentage of red blood cells in blood), and serum cholesterol levels change in patients with Parkinson's disease long before the onset of motor symptoms.

18 Jan 2021